Form 4: Elisabeth Bjork, Rocket Pharmaceuticals Director, Reports Stock Option Grant

Director Elisabeth Bjork reports the acquisition of stock options for 607 shares of Rocket Pharmaceuticals common stock.

Summary

• Elisabeth Bjork, a director of Rocket Pharmaceuticals, reported a transaction on September 26, 2024.
• Bjork acquired stock options for 607 shares of Rocket Pharmaceuticals' common stock at an exercise price of $17.60.
• The options vest fully on September 26, 2025, and expire on September 26, 2034.
• The report was filed on October 29, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative performance, but rather aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management and shareholders.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates